This content is from: Premium
How ValueAct Shook Off Its Big Loss from Valeant
The hedge fund firm, headed by Jeff Ubben, did not suffer the same fate as other major shareholders of the ailing pharmaceutical concern.
Valeant Pharmaceuticals International Inc. headquarters in Bridgewater Township, New Jersey, U.S., on Aug. 4, 2016. (Photo credit: Ron Antonelli/Bloomberg).It is no secret that the shares of Valeant Pharmaceuticals International have destroyed the performance of a number of hedge funds. Just look at the double-digit losses suffered by its two biggest
To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.